Speaker Profile
Ph.D., Professor, Stanford
Biography
Nathanael S. Gray, Ph.D., is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford University and Co-Director of Cancer Drug Discovery at Stanford Cancer Institute. A chemical biologist and medicinal chemist, he develops small molecules that probe disease biology and can serve as starting points for new therapeutics. His laboratory is particularly known for kinase inhibitor design, covalent drug discovery, targeted protein modulation, and strategies to overcome drug resistance in cancer. Earlier in his career at the Genomics Institute of the Novartis Research Foundation, Dr. Gray helped develop covalent inhibitors targeting the EGFR T790M resistance mutation, work that contributed to the scientific foundation for later-generation EGFR therapies. He subsequently built a drug-discovery program at Harvard Medical School and Dana-Farber Cancer Institute before joining Stanford in 2021. Dr. Gray earned his undergraduate and doctoral degrees at the University of California, Berkeley. His research tightly integrates synthetic chemistry, structural biology, genetics, and translational oncology to create therapeutically actionable molecules.
AI and Data Sciences Showcase:
Medlink Global
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Catriona Jamieson, UC San Diego
PMWC Award Ceremony
• Emmanuelle Charpentier, Max Planck (J. Craig Venter Visionary Award · Nobel Laureate)
• Jay Bradner, Amgen (Pioneer)
• Adrian Krainer, Cold Spring Harbor Laboratory (Luminary)
• Randy Schekman, UC Berkeley (Nobel Laureate, Pioneer)
Featured Speakers
• Emmanuelle Charpentier, Max Planck
• Randy Schekman, UC Berkeley
• Jay Bradner, Amgen
• Adrian Krainer, Cold Spring Harbor Laboratory
• Alexis C. Komor, UC San Diego
• Nicole Gaudelli, GV
• Rachel Haurwitz, Caribou Bio
• Gene Yeo, UC San Diego
• Timothy Yu, Boston Children's / Harvard
• Shicheng Guo, Arrowhead Pharmaceuticals
• Mark A. Kay, Stanford
• Niren Murthy, UC Berkeley
• Ben Deverman, Broad Institute
• Stanley Crooke, n-Lorem / Ionis
Programming Protein Fate
Molecular glues, degraders, and induced proximity crossing into medicines.
Genome Editing Beyond the First Wave
Base, prime, and CRISPR-enabled editing moving from correction to clinic.
RNA Editing, Splice Modulation & Programmable RNA
RNA editing, ASOs, and splice modulation with chemistry already reaching patients.
In Vivo Delivery & Vector Engineering
AAV, LNP, and next-generation vectors that decide what is treatable.
From N-of-1 to Platform
Evidence, CMC, regulation, and access for individualized genetic medicines.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
